Volume 29, Issue 12 pp. 1099-1106
ORIGINAL ARTICLE

HBsAg seroconversion in de novo hepatitis B virus-infected paediatric liver transplant recipients with anti-viral therapy

Chong Dong

Chong Dong

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Zhuolun Song

Zhuolun Song

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Chao Sun

Chao Sun

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Kai Wang

Kai Wang

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Jing Chen

Jing Chen

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Wei Zhang

Wei Zhang

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Di Wu

Di Wu

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Weiping Zheng

Weiping Zheng

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Yang Yang

Yang Yang

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Hong Qin

Hong Qin

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Chao Han

Chao Han

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Fubo Zhang

Fubo Zhang

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Zhen Wang

Zhen Wang

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Min Xu

Min Xu

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Guofeng Zhang

Guofeng Zhang

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Enbo Xie

Enbo Xie

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Junli Jiao

Junli Jiao

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Shunqi Cao

Shunqi Cao

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
Wei Gao

Corresponding Author

Wei Gao

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Correspondence

Wei Gao, Department of Paediatric Transplantation, Organ Transplant Center, Tianjin First Central Hospital, No.24 Fukang Road, Nankai District, 300192 Tianjin, China.

Email: [email protected]

Search for more papers by this author
Zhongyang Shen

Zhongyang Shen

Department of Paediatric Transplantation, Tianjin First Central Hospital, Tianjin, China

Tianjin Key Laboratory for Organ Transplantation, Tianjin, China

Search for more papers by this author
First published: 12 September 2022

Abstract

We investigated the clinical characteristics and therapeutic strategies for paediatric liver transplant (PLT) recipients who experienced de novo hepatitis B virus infection and the features of HBsAg seroconversion. A total of 821 PLT were performed in HBV-free recipients between January 2013 and January 2019 in Paediatric Organ Transplant Center, Tianjin First Central Hospital. Twenty-one recipients developed de novo HBV infection, the clinical data were analysed. The overall incidence of de novo HBV infection was 2.5%. Only one recipient received an HBcAb-negative graft, 20 recipients received HBcAb-positive grafts. The incidence of de novo HBV infection in HBcAb-negative and HBcAb-positive graft recipients were 0.2% and 6.3%, respectively. Fifteen de novo HBV-infected recipients showed HBsAg seroconversion, the incidence of HBsAg seroconversion was 71.4%. The median time from the diagnosis of de novo HBV infection to HBsAg seroconversion was 15 (1, 73) months. Recipients with hepatitis B surface antigen (HBsAg) titre <1000 IU/L and negative hepatitis B e antigen (HBeAg) at the time of de novo HBV infection diagnosis were more likely to achieve HBsAg seroconversion. Nucleotide analogues were effective in treating recipients with de novo HBV infection. De novo HBV infection does not impact liver graft function as well as recipient and graft survival rate. De novo HBV infection does not impact PLT recipient outcomes under close monitoring and appropriate treatment. High incidence of HBsAg seroconversion can be achieved after anti-viral therapy.

CONFLICT OF INTEREST

The authors have no potential conflict of interest to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.